Bone Morphogenic Protein Receptor type 2 mutation carriers research hub
8 indexed studies · 6 currently recruiting
- authorisedHuman Pharmacology (Phase I)- First administration to humans
Targeting fibrotic tissue with a radioactive-labelled Fibrobody, visible using a full-body PET/CT scan (FibroVision)
The FibroVision study is testing a new type of medical scan to detect organ scarring, also known as fibrosis. Participants receive a small injection of a specialised tracer called a Fibrobody, followed by a full-body PET/CT scan. Researchers want to find out if this scan is safe and effective.
Netherlands - recruitingPHASE3
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
This study looks at new medicines, retatrutide and tirzepatide, for adults with a type of fatty liver disease called MASLD. It aims to see if these drugs can help prevent serious liver problems. Some participants will receive a dummy drug (placebo) to compare.
United States · Argentina · Australia - not yet recruitingPHASE3
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
This study looks at a new medicine called survodutide for people who are overweight or obese and have a type of fatty liver disease. Researchers want to see if this medicine can help improve the health and function of their heart. Participants receive weekly injections, either the medicine or a dummy injection.
United States · China · Germany - recruitingPHASE1, PHASE2
A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
This study is testing a new drug called ALN-CIDEB for people with fatty liver conditions, MASLD and MASH. It aims to check how safe the drug is, if it causes side effects, and how it affects liver fat.
United States · United Kingdom - recruitingPHASE1
COmmencing Menopausal HOrmone Replacement Therapy and the Effect on Metabolic-dysfunction Associated Steatotic Liver Disease: a Pilot Mechanistic Study
This study looks at how hormone replacement therapy (HRT) affects fat in the liver and body in women going through menopause. Researchers want to understand if HRT can help prevent or manage fatty liver disease, a common problem after menopause.
United Kingdom - recruitingNA
The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
This study looks at whether a daily pectin supplement, found in foods like citrus peel, can reduce inflammation and improve gut health in adults with a common liver condition called MASLD. Researchers want to see if it helps with overall health.
United Kingdom - not yet recruitingPHASE4
Digital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
This study looks at whether a digital app, Gro Health, can help people with a liver condition called MASLD reduce liver scarring. It checks if the app improves diet, exercise, weight, and general health over 12 months.
United Kingdom - active not recruitingPHASE2
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
This study is looking into a new medicine called efinopegdutide for a liver condition called MASH. We want to see if it can help reduce liver fat, swelling, and scarring in people with MASH and mild scarring. It also checks how safe the medicine is.
United States · Australia · Canada